Fulminant type 1 diabetes is a unique subtype of type 1 diabetes and is characterized by an abrupt onset of severe hyperglycemia/ketoacidosis and severe β-cell damage that is preceded by flu-like symptoms ([@B1]--[@B3]). Recently, we have reported unique enterovirus-induced mechanisms for β-cell destruction involving CXC chemokine ligand 10 (CXCL10) and chemokine receptor CXCR3 in fulminant type 1 diabetes ([@B4]).

In this study, we examined the in situ status of innate and adaptive immunity of enterovirus-induced fulminant type 1 diabetes. This includes expression of Toll-like receptors (TLRs) TLR3 and TLR4 and cytoplasmic retinoic acid--inducible gene I (RIG-I)-like receptors (RLRs) RIG-I and melanoma differentiation--associated gene-5 (MDA5). TLRs and RLRs are major receptor systems for detecting RNA viruses like enterovirus ([@B5]). As interferon (IFN)-α and -β potentially inhibit viral replication and enhance cytotoxic β-cell immunity ([@B6]), their expression, cytokine/chemokine expression, and activity of dendritic cells (DCs)/macrophages, CD4+ forkhead box P3 (Foxp3)+ regulatory T cells (Tregs) in affected islet cells were examined.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Patients. {#s6}
---------

Clinical profiles of three autopsied patients with fulminant type 1 diabetes have been reported ([@B4]). Briefly, case 1 was a 14-year-old boy who died from diabetic ketoacidosis, following flu-like symptoms 5 days earlier. Case 2 was a 25-year-old man who died from diabetic ketoacidosis, following sudden symptoms of nausea and epigastralgia 2 days earlier. Case 3 was a 29-year-old man who died from diabetic ketoacidosis, following slight fever, nausea, and vomiting 2 days earlier.

Control subjects. {#s7}
-----------------

Pancreatic tissues from 10 nondiabetic men (mean age ± SD, 62 ± 10 years) with gastric carcinoma who had undergone partial pancreatectomy and from five autopsied nondiabetic men (65 ± 11 years) were used as nondiabetic control subjects for immunohistochemical analysis. Pancreatic tissues from four autopsied type 1 diabetic patients (44 ± 9 years) who had histopathological insulitis and glutamic acid decarboxylase autoantibodies (titer: 3.0 ± 1.5 U/mL, cutoff \<1.5) were examined as type 1 diabetic control subjects.

Immunostaining. {#s8}
---------------

Methods for immunohistochemical analyses have been reported previously ([@B4]). Primary antibodies used in this study are listed in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1). The definition of insulitis and frequencies of insulitis and mononuclear cell (MNC) phenotypes in islets of cases 1--3 have been documented previously ([@B4]). The number of pancreatic acinar cells surrounded by CD8+ T cells was counted in the randomly selected 60 photos of pancreatic section in each case. A confocal laser-scanning microscope, Fluoview FV1000 (Olympus, Tokyo, Japan), was also used.

Measurement of serum IFN-γ. {#s9}
---------------------------

We obtained sera from 18 patients with fulminant type 1 diabetes (age \[range\]: 32.3 ± 13.5 \[17--58\] years, sex \[man/woman\]: 12/6, duration: 31.0 ± 64.1 \[0--240\] days), 27 patients with typical type 1 diabetes (age: 31.4 ± 14.7 \[6--55\] years, sex: 12/15, duration: 12.5 ± 25.4 \[0.1--108\] months), and 30 nondiabetic control subjects (age: 33.3 ± 13.3 \[20--60\] years, sex: 17/13). Serum level of IFN-γ was measured by ELISA (PBL Biomedical Laboratories, R&D Systems, Piscataway, NJ).

Ethics. {#s10}
-------

The Ethics Committee of the University of Yamanashi approved all of the procedures performed in this study. All patients gave informed consent for measuring serum IFN-γ.

Statistical analysis. {#s11}
---------------------

Differences in variables between groups were compared using Student *t* test and ANOVA. Fisher exact test was used to compare frequencies of islets. Values are expressed as means ± SD unless otherwise mentioned.

RESULTS {#s12}
=======

MDA5, RIG-I, and enterovirus-capsid protein expression. {#s13}
-------------------------------------------------------

MDA5 was strongly expressed in β-cells, α-cells, and other types of islet cells of fulminant type 1 diabetic pancreata ([Fig. 1*A*--*D*](#F1){ref-type="fig"}). In nondiabetic control and type 1 diabetic control subjects, weak MDA5 expression was observed in a few α-cells ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)). Significant expression of RIG-I was observed preferentially in β-cells in all three patients with fulminant type 1 diabetes ([Fig. 1*E*--*H*](#F1){ref-type="fig"}), yet it was not expressed in nondiabetic and type 1 diabetic control subjects ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)). Enterovirus-capsid protein (VP1) was detected in β- and non--β-cells of fulminant type 1 diabetic pancreata confirming our previous report ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)) ([@B4]) but not type 1 diabetic control and nondiabetic control subjects.

![Intracytoplasmic double-stranded virus RNA receptor expression in enterovirus-associated human fulminant type 1 diabetes. *A*--*C*: Triple-immunostaining of MDA5 (*A*), insulin (*B*), and glucagon (*C*). The merged image (*D*) demonstrates hyperexpression of MDA5 in β-cells (light blue, arrowheads), α-cells (orange), and other types of islet cells (green, arrows) (×400, case 2). Triple-immunostaining of RIG-I (*E*), insulin (*F*), and glucagon (*G*) is also shown. The merged image (*H*) demonstrates specific expression of RIG-I in β-cells (light blue, arrowheads) (×400, case 2). (A high-quality digital representation of this figure is available in the online issue.)](884fig1){#F1}

TLR3 and TLR4 expression. {#s14}
-------------------------

Both TLR3 and TLR4 were expressed in MNCs that had infiltrated islets of fulminant type 1 diabetic pancreata but not nondiabetic and type 1 diabetic control subjects ([Table 1](#T1){ref-type="table"}).

###### 

Frequency of islets with MNCs that express TLR3, TLR4, CD11c, CD4+Foxp3, and FasL in three fulminant type 1 diabetic cases, and nondiabetic and type 1 diabetic control subjects

                                                Frequency of TLR3+ MNCs (%)   Frequency of TLR4+ MNCs (%)   Frequency of CD11c+ cells (%)   Frequency of CD4+ Foxp3+ cells (%)   Frequency of FasL+ MNCs (%)
  --------------------------------------------- ----------------------------- ----------------------------- ------------------------------- ------------------------------------ ----------------------------------
  Case                                                                                                                                                                           
   1                                            11.3 (7/62)                   1.6 (1/62)                    95.9 (70/73)                    0 (0/75)                             82.6 (38/46)
   2                                            5.0 (2/40)                    1.8 (1/56)                    100 (64/64)                     0 (0/63)                             90.0 (36/40)
   3                                            18.8 (6/32)                   9.4 (5/53)                    91.2 (52/57)                    0 (0/70)                             95.2 (40/42)
  Mean                                                                                                                                                                           
   FT1D (*n* = 3)                               11.7 ± 6.9 (15/134)           4.3 ± 4.4 (7/171)             95.7 ± 4.4 (186/194)            0 (0/208)                            89.3 ± 6.3 (114/128)
   Nondiabetic control subjects (*n* = 15)      0 (0/652)                     0.3 ± 0.6 (0--1.7) (3/742)    0.2 ± 0.5 (0--1.4) (2/863)      0 (0/692)                            0.3 ± 0.7 (0--1.9) (3/763)
   Type 1 diabetic control subjects (*n* = 4)   0 (0/228)                     0 (0/284)                     2.4 ± 4.2 (0--9.8) (10/392)     0 (0/351)                            18.2 ± 16.9 (3.8--46.6) (81/417)
  *P* value FT1D vs. nondiabetes                \<0.0001                      \<0.003                       \<0.0001                        NS                                   \<0.0001
   FT1D vs. type 1 diabetes                     \<0.002                       NS                            \<0.0001                        NS                                   =0.0005
   Nondiabetes vs. type 1 diabetes              NS                            NS                            NS                              NS                                   =0.001

Values are means ± SD unless otherwise indicated. FT1D, fulminant type 1 diabetes.

IFN-α, IFN-β, interferon regulatory factor-7, and major histocompatibility complex class I expression. {#s15}
------------------------------------------------------------------------------------------------------

In all three pancreata of the patients with fulminant type 1 diabetes, IFN-α and -β~1~ were strongly expressed ([Fig. 2*A*--*F*](#F2){ref-type="fig"}). Some MNCs that had infiltrated around or in islets and pancreatic acinar and ductal cells also expressed theses cytokines in fulminant type 1 diabetes ([Fig. 2*A* and *B*](#F2){ref-type="fig"}) but not in either control subject. The numbers of pancreatic acinar cells surrounded by CD8+ T cells were 11/mm^2^, 24/mm^2^, and 22/mm^2^, respectively, in the pancreatic sections of cases 1, 2, and 3. Most IFN-α--expressing cells were β-cells, α-cells, and islet non--β- and non--α-cells ([Fig. 2*C*--*F*](#F2){ref-type="fig"}). Interferon regulatory factor (IRF)-7 ([@B7]) was strongly expressed in β- and α-cells ([Fig. 2*G*--*I*](#F2){ref-type="fig"}) and mostly stained around and in the nucleus of the islet cells ([Fig. 2*G*](#F2){ref-type="fig"}). Major histocompatibility complex class I (MHC-I) was hyperexpressed in all islet cell subsets of fulminant type 1 diabetic pancreata ([Fig. 2*J*](#F2){ref-type="fig"}). Nondiabetic control and type 1 diabetic control subjects did not show expression of IFN-α, IFN-β~1~, or IRF-7 and hyperexpression of MHC-I in their islets.

![Immunohistochemical staining of IFN-α, IFN-β~1~, IRF-7, and MHC-class I in a pancreas with fulminant type 1 diabetes (×200, case 2). *A* and *B*: Immunostaining of IFN-α (*A*) and IFN-β~1~ (*B*). *C*--*F*: Triple-immunohistochemical staining of IFN-α (*C*), insulin (*D*), and glucagon (*E*). A merged image (*F*) demonstrates a high proportion of β-cells and α-cells expressing IFN-α. Color balance of *F* has been adjusted. *G*--*I*: Double-immunohistochemical staining of IRF-7 (*G*) and insulin (*H*). Insert in *G* demonstrates strong peri- and intranuclear staining of IRF-7, indicating translocation of IRF-7 from the cytoplasm to the nuclease, thus acting as an activated transcription factor. The merged image (*I*) shows strong expression of IRF-7 in both islet β-cells and islet non--β-cells. Color balance of *I* has been adjusted. *J*: Triple-immunostaining shows MHC-class I molecules are hyperexpressed at the cell surface (green) in β-cells (blue), α-cells (orange), and non--β-/non--α- (nonstained for cytoplasm) islet cells. *K*--*N*: Triple-immunostaining of CD11c (*K*), insulin (*L*), and MHC-II (*M*). Merged image (*N*) demonstrates that CD11c+ cells expressing MHC-II migrate around and into the islets (×200, case 1). *O*: Confocal microscopic demonstration of intraislet CD11c+ cells (green), showing phagocytosis of the unprocessed β-cell antigen, insulin (red; arrowheads) (×400, case 1). *P*: Merged image of triple-immunostaining of CD11c (red), CD68 (green), and insulin (blue). Arrowheads indicate positive cells (yellow) both for CD11c and CD68 (×200, case 1). (A high-quality digital representation of this figure is available in the online issue.)](884fig2){#F2}

CD11c+ cells in islets. {#s16}
-----------------------

Remarkable CD11c+ cells migration to the islets was observed in most islets of fulminant type 1 diabetic pancreata ([Table 1](#T1){ref-type="table"}). Intraislet CD11c+ cells expressed MHC class-II molecules ([Fig. 2*K*--*N*](#F2){ref-type="fig"}). Confocal microscopy showed that some CD11c+ cells contained β-cell debris positive for insulin ([Fig. 2*O*](#F2){ref-type="fig"}). Such findings were not observed in islets of nondiabetic or type 1 diabetic control subjects. Most CD11c+ cells were also positive for CD1a and some for CD68 ([Fig. 2*P*](#F2){ref-type="fig"}), likely representing DCs and macrophage subsets. CD56+ or CD57+ NK cells and Tregs (CD4+ Foxp3+ cells) were not detected in or around islets of fulminant type 1 diabetic pancreata and either control. Tregs, CD4+ Foxp3+ cells, were not detected in or around the islets or in exocrine regions of the pancreas in fulminant type 1 diabetic, nondiabetic control, or type 1 diabetic control subjects ([Table 1](#T1){ref-type="table"}).

IL-18, IFN-γ, and CXCL10 expression. {#s17}
------------------------------------

IL-18 was expressed in islet cells in all three fulminant type 1 diabetes ([Fig. 3*A* and *E*](#F3){ref-type="fig"}). Most residual β-cells expressed both IFN-γ and IL-18 ([Fig. 3*G* and *H*](#F3){ref-type="fig"}). IL-18, IFN-γ, and CXCL10 colocalized in most β- and islet non--β-cells ([Fig. 3*A*--*H*](#F3){ref-type="fig"}). IL-12 was not expressed in any cells in affected pancreata. A few islets of type 1 diabetic control subjects (mean \[range\]: 2.8% \[0--5.2\]) expressed IL-18 and IFN-γ but not CXCL10. Nondiabetic control subjects did not express IL-18, IFN-γ, and CXCL10.

![Immunohistochemical staining of IL-18, insulin, CXCL10, IFN-γ, and FasL. *A*--*D*: Triple-immunostaining of IL-18 (*A*), insulin (*B*), and CXCL10 (*C*). The merged image (*D*) shows that most β-cells express both IL-18 and CXCL10 (arrowheads). Some islet non--β-cells also express IL-18 and CXCL10 (orange, arrows) (×400, case 2). *E*--*H*: Triple-immunostaining of IL-18 (*E*), insulin (*F*), and IFN-γ (*G*). The merged image (*H*) shows that most β-cells express both IL-18 and IFN-γ (arrowheads) and that some islet non--β-cells also express IFN-γ (red) (×400, case 2). *I*: Serum levels of IFN-γ in patients with fulminant type 1 diabetes (FT1D) or with typical acute-onset type 1 diabetes (AT1D) and nondiabetic control (CT) subjects. Values are expressed as means ± SE; \**P* \< 0.05. *J*: Immunostaining of Fas in islets affected by fulminant type 1 diabetes (brown) demonstrates strong expression of Fas in islet cells (×200, case 2). *K*--*M*: Double-immunofluorescent staining of insulin (*K*) and FasL (*L*). The merged image (*M*) shows that FasL-positive cells infiltrate the islets (×400, case 3). Color balance of *M* has been adjusted. (A high-quality digital representation of this figure is available in the online issue.)](884fig3){#F3}

Serum IFN-γ levels in patients with fulminant type 1 diabetes. {#s18}
--------------------------------------------------------------

Serum levels of IFN-γ in patients with fulminant type 1 diabetes were approximately three times higher than those in nondiabetic and type 1 diabetic control subjects ([Fig. 3*I*](#F3){ref-type="fig"}).

Fas expression in islet cells and infiltration of islet Fas-ligand--bearing MNCs. {#s19}
---------------------------------------------------------------------------------

Elevated expression of Fas in islet cells coincided with marked MNC infiltration in fulminant type 1 diabetic pancreata ([Fig. 3*J*](#F3){ref-type="fig"}). The subsets of islet cells with Fas expression were mostly β-cells. Fas-ligand (FasL)-bearing MNCs infiltrated most islets of fulminant type 1 diabetic pancreata ([Fig. 3*K*--*M*](#F3){ref-type="fig"}) ([Table 1](#T1){ref-type="table"}). In islet cells of nondiabetic control and type 1 diabetic control subjects, Fas was not expressed ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)). FasL-bearing MNC infiltration of islets was observed in type 1 diabetic but not nondiabetic control subjects ([Table 1](#T1){ref-type="table"}) ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)).

Expression of retinoic acid--receptor responder 3 and activated caspases 8, 9, and 3 in islet β-cells. {#s20}
------------------------------------------------------------------------------------------------------

Retinoic acid--receptor responder 3 (RARRES3) ([@B8],[@B9]) was expressed in β-cells of fulminant type 1 diabetic pancreata ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)). Cleaved caspase 8, a marker of the Fas-mediated extrinsic apoptotic pathway, cleaved caspase 9, a marker of the activated non--Fas-mediated apoptotic pathway, and activated caspases 3, a marker of the end stage of β-cell apoptosis, were expressed specifically in islet β-cells ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)). In islets of autopsied nondiabetic control subjects, RARRES3, cleaved caspases 8, -9, and -3 were not expressed ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)). In type 1 diabetic control subjects, RARRES3, cleaved caspases 8, -9, and -3 were expressed weakly in some islet β-cells ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1)).

DISCUSSION {#s21}
==========

Both RIG-I and MDA5 were strongly expressed in β-cells of fulminant type 1 diabetic pancreata. MDA5 was also hyperexpressed in α-cells and non−β-/non--α-cells in affected islets. Hyperexpression of RIG-I and MDA5 with expression of IFN-α and -β~1~ in β-cells suggests a crucial role of RIG-I and MDA5 for sensing and responding to enterovirus infection in the pancreas of patients with fulminant type 1 diabetes. Mutations of MDA5 genes have been implicated in reducing the risk of type 1 diabetes ([@B10]). Reports also noted RIG-I mRNA expression in human islets infected with Coxsackievirus B3 and B5 ([@B11],[@B12]). We showed that IRF-7, a master transcription factor of IFN-α and -β ([@B7]), translocated to the nucleus and that IFN-α and -β, essential factors that protect β-cells against viral infection ([@B6]), were strongly expressed in both β- and α-cells. These results indicate that all islet cells are in an activated state of innate immunity in response to enterovirus in patients with fulminant type 1 diabetes.

Increased TLR3+ MNCs that infiltrate affected islets should participate in sensing viral RNA and subsequently destroy β-cells with RIG-I-- and MDA5-initiated proinflammatory signal axes in the innate immune response against Coxsackievirus B3 ([@B13]). Intra- and peri-islet DCs and macrophage subsets drastically increased in number and showed active phagocytosis of enterovirus-infected β-cells, whereas MHC-I was hyperexpressed in all islet subsets. Some DCs and macrophage subsets also expressed MHC-II molecules. Activated innate immune responses including virus sensing by RIG-I and MDA5 with subsequent IFN-α and -β production and DC and macrophage activation will not only protect for enteroviral infection by upregulating RIG-I and MDA5 ([@B12],[@B14]) but will also enhance the adaptive immunity cascades for islet cell destruction ([@B6],[@B15],[@B16]). Indeed, patients with fulminant type 1 diabetes showed elevated serum levels of IFN-γ.

CD4+ Foxp3+ cells, which represent a pivotal subset of Tregs, were not observed in or around the islets of fulminant type 1 diabetic pancreata, suggesting that the extremely polarized local condition to predominance for Th1 in response to enteroviral infection suppresses Treg differentiation from naive T CD4+ precursors ([@B17]). In turn, the Treg-depleted islet condition enhances Th1 cytokine (i.e., IFN-γ) generation.

Notably, IL-18, an IFN-γ--inducing factor, was extensively expressed in islet cells of infected fulminant type 1 diabetic pancreata. In response to viral infection, IL-18 is promptly secreted from virus-activated macrophages, DCs, and T cells ([@B18]), stimulating production of IFN-γ synergistically with IFN-α and -β through a unique pathway that sometimes occurs independently of IL-12 or NK cells ([@B19]). Conversely, IL-18 can be induced by IFN-γ alone or in combination with other cytokines in islet β-cells ([@B20]). Thus, for fulminant type 1 diabetes, enterovirus itself or enterovirus-activated T cells and macrophages most likely infiltrate islets to induce IL-18 production in these cells. In addition, IFN-α and -β, produced in islet cells and islet-infiltrating MNCs, can enhance IL-18--mediated signaling ([@B21]). Subsequently, islet-secreted IL-18 may induce IFN-γ production via receptors on the islet cells or islet stromal cells in an autocrine/paracrine manner. Once this positive autocrine/paracrine circuit for production of IL-18, IFN-γ, and CXCL10 is established in islet cells, destructive mechanisms involving CXCR3+ T cells and macrophages might persist until complete destruction of the β-cells ([@B4]).

We found that Fas was highly expressed in affected islet β-cells and islet-infiltrating FasL+ cells. Taken together with the finding that MHC-I and IFN-α, -β, and -γ were strongly expressed in affected islet cells, effecter mechanisms for β-cell apoptosis in fulminant type 1 diabetes are likely mediated in part by MHC-I and by the Fas-FasL pathway ([@B22]). Inflammation-induced Fas-FasL expression in β-cells was reported to lead to rapid and massive β-cell destruction ([@B23]). Other apoptotic mechanisms through the IFN-γ--dependent JAK/STAT pathway ([@B24]) and innate immune pathway ([@B25]) will also exert β-cell destruction.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0795/-/DC1>.
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